EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Acrokeratosis paraneoplastica (Bazex syndrome): a systematic review and quantitative analysis of 106 cases

Mustafa Sefa Isin iD, Mehmet Berke Isler iD, Amor Khachemoune iD

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag376 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Oncologist, 2026. Verfasst von Mustafa Sefa Isin und 2 weiteren Autor:innen. Beteiligte Einrichtung: International School of Medicine, Istanbul Medipol University, Istanbul, 34815, Turkey. Hauptthemen laut MEDLINE: Basal Cell Carcinoma, Hypotrichosis, Skin Neoplasms, Paraneoplastic Syndromes. Die Arbeit nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acrokeratosis paraneoplastica (Bazex syndrome) is an obligate paraneoplastic dermatosis characterized by symmetrical acral psoriasiform lesions and nail dystrophy.

Methods

We conducted a PRISMA-compliant systematic review of 99 publications (89 case reports, 10 case series) describing 106 patients to re-examine the syndrome’s epidemiology, oncologic associations, clinical features, treatment response, and prognosis.

Results

The mean age at onset was 63.5 years (median: 62.5 years; interquartile range [IQR]: 57-70 years); men comprised 72.6% (n = 77; 95% CI, 63.5%-80.2%), yielding a male-to-female ratio of 2.7:1. Squamous cell carcinoma accounted for 51.9% (55/106; 95% CI, 42.5%-61.2%) of associated malignancies, followed by adenocarcinomas (18.9%; 95% CI, 12.6%-27.4%) and hematologic neoplasms (8.5%; 95% CI, 4.5%-15.4%). Cutaneous lesions preceded the cancer diagnosis in 80.6% (83/103) of patients with reported chronology, with a median lead-time of 5 months (IQR 2-10 months). Nail involvement was documented in 73.6% (78/106). Following oncologic therapy, complete cutaneous clearance occurred in 36.8% (95% CI, 28.2%-46.3%) and partial improvement in 30.2% (95% CI, 22.3%-39.5%) of cases. In univariable analyses, distant metastasis (P = .021) and an aerodigestive primary site (P = .026) were nominally associated with reported mortality, although neither remained significant after multiple-comparison correction.

Conclusion

Bazex syndrome should be suspected in patients presenting with treatment-resistant acral psoriasiform lesions and nail dystrophy, prompting rigorous malignancy screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basal Cell CarcinomaHypotrichosisSkin NeoplasmsParaneoplastic SyndromesHumansMaleFemaleMiddle AgedAgedCase Reports as TopicPrognosis

Stichwörter der Autor:innen

Acrokeratosis paraneoplasticaBazex syndromeParaneoplastic dermatosisPsoriasiform lesionsSquamous cell carcinoma

Autor:innen und Institutionen

  • International School of Medicine, Istanbul Medipol University, Istanbul, 34815, Turkey.
  • Premier Dermatology, Ashburn, VA 20147, USA.
  • Department of Dermatology, Istanbul Medipol University, International School of Medicine, Istanbul, 34214, Turkey.

ORCID-Profile: Mustafa Sefa Isin, Mehmet Berke Isler, Amor Khachemoune

Zitieren

APA

Isin, M. S., Isler, M. B., & Khachemoune, A. (2026). Acrokeratosis paraneoplastica (Bazex syndrome): a systematic review and quantitative analysis of 106 cases. The Oncologist. https://doi.org/10.1093/oncolo/oyag376

Vancouver

Isin MS, Isler MB, Khachemoune A. Acrokeratosis paraneoplastica (Bazex syndrome): a systematic review and quantitative analysis of 106 cases. The Oncologist. 2026. doi:10.1093/oncolo/oyag376

BibTeX
@article{Isin2026,
  author = {Isin, Mustafa Sefa and Isler, Mehmet Berke and Khachemoune, Amor},
  title = {Acrokeratosis paraneoplastica (Bazex syndrome): a systematic review and quantitative analysis of 106 cases},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag376}
}
Kostenlos starten →